Erratum: Telmisartan attenuates diabetic nephropathy by suppressing oxidative stress in db/db mice (Nephron - Experimental Nephrology (2012) 121 (e97-e108) DOI: 10.1159/000343102);Telmisartan attenuates diabetic nephropathy by suppressing oxidative stress in db/db mice

Nephron - Experimental Nephrology

Volumn 121, Issue 3-4, 2013, Pages 46-

  Sato Horiguchi, Chikage ^a   Ogawa, Daisuke ^a   Wada, Jun ^a   Tachibana, Hiromi ^a   Kodera, Ryo ^a,b   Eguchi, Jun ^a   Nakatsuka, Atsuko ^a   Terami, Naoto ^a   Shikata, Kenichi ^a,b   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Diabetic nephropathy; Inflammation; Oxidative stress; Reactive oxygen species

Indexed keywords

4 HYDROXYDEOXYGUANOSINE; 8 HYDROXYDEOXYGUANOSINE; ALBUMIN; HYDROETHIDINE; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL EXPANSION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DISEASE MARKER; DRUG EFFECT; GENE EXPRESSION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY EPITHELIUM; KIDNEY PARENCHYMA; KIDNEY PROXIMAL TUBULE; MACROPHAGE; MALE; MESANGIUM; MICROSCOPY; MOUSE; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENAL PROTECTION;

EID: 84874784808     PISSN: None     EISSN: 16602129     Source Type: Journal    
DOI: 10.1159/000355989     Document Type: Erratum

References (33)

1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
2. Kaiyala KJ, Schwartz MW: Toward a more complete (and less controversial) understanding of energy expenditure and its role in obesity pathogenesis. Diabetes 2011; 60: 17-23.
3. Dyson PA: The therapeutics of lifestyle management on obesity. Diabetes Obes Metab 2010; 12: 941-946.
4. Reutens AT, Atkins RC: Epidemiology of diabetic nephropathy; in Lai KN, Tang SCW (eds): Diabetes and the Kidney. Contrib Nephrol. Basel, Karger, 2011, vol 170, pp 1-7.
5. Ruggenenti P, Cravedi P, Remuzzi G: The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010; 6: 319-330.
6. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U: Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000; 278:F817-F822. (Pubitemid 30351084)
7. Kasiske BL, Napier J: Glomerular sclerosis in patients with massive obesity. Am J Nephrol 1985; 5: 45-50. (Pubitemid 15195137)
8. Kopple JD, Feroze U: The effect of obesity on chronic kidney disease. J Ren Nutr 2011; 21: 66-71.
9. Stanton RC: Oxidative stress and diabetic kidney disease. Curr Diab Rep 2011; 11: 330-336.
10. Kanwar YS, Sun L, Xie P, Liu FY, Chen S: A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 2011; 6: 395-423.
11. Singh DK, Winocour P, Farrington K: Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol 2011; 7: 176-184.
12. Lopes de Faria JB, Silva KC, Lopes de Faria JM: The contribution of hypertension to diabetic nephropathy and retinopathy: the role of inflammation and oxidative stress. Hypertens Res 2011; 34: 413-422.
13. Tesch GH, Lim AK: Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. Am J Physiol Renal Physiol 2011; 300:F301-F310.
14. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S: Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30: 1577-1578. (Pubitemid 46871174)
15. Uzu T, Sawaguchi M, Maegawa H, Kashiwagi A: Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007; 30: 1581-1583. (Pubitemid 46871176)
16. Bakris G, Burgess E, Weir M, Davidai G, Koval S: Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008; 74: 364-369. (Pubitemid 352002795)
17. Sugiyama H, Kobayashi M, Wang DH, Sunami R, Maeshima Y, Yamasaki Y, Masuoka N, Kira S, Makino H: Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. Nephrol Dial Transplant 2005; 20: 2670-2680. (Pubitemid 41672265)
18. Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR: Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 2009; 60: 373-381.
19. Fouad AA, Qureshi HA, Al-Sultan AI, Yacoubi MT, Al-Melhim WN: Nephroprotective effect of telmisartan in rats with ischemia/reperfusion renal injury. Pharmacology 2010; 85: 158-167.
20. Lakshmanan AP, Watanabe K, Thandavarayan RA, Sari FR, Harima M, Giridharan VV, Soetikno V, Kodama M, Aizawa Y: Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-( 1-7) mas receptor expression associated with its PPAR-gamma agonist action. Free Radic Res 2011; 45: 575-584.
21. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, Nagase R, Wada J, Shikata Y, Makino H: Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003; 52: 2586-2593. (Pubitemid 37210549)
22. Okada T, Wada J, Hida K, Eguchi J, Hashimoto I, Baba M, Yasuhara A, Shikata K, Makino H: Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes 2006; 55: 1666-1677. (Pubitemid 44324119)
23. Kitamura S, Maeshima Y, Sugaya T, Sugiyama H, Yamasaki Y, Makino H: Transforming growth factor-beta 1 induces vascular endothelial growth factor expression in murine proximal tubular epithelial cells. Nephron Exp Nephrol 2003; 95:e79-e86.
24. Shigenaga MK, Gimeno CJ, Ames BN. Urinary 8-hydroxy-2'-deoxyguanosine as a biological marker of in vivo oxidative DNA damage. Proc Natl Acad Sci USA 1989; 86: 9697-9701. (Pubitemid 20030700)
25. Dong YF, Liu L, Kataoka K, Nakamura T, Fukuda M, Tokutomi Y, Nako H, Ogawa H, Kim-Mitsuyama S: Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia 2010; 53: 180-191.
26. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H: Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54: 965-978.
27. Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, Hirakawa M, Taniguchi M, Masutani K, Iida M: Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant 2011; 26: 2475-2484.
28. Sun L, Xie P, Wada J, Kashihara N, Liu FY, Zhao Y, Kumar D, Chugh SS, Danesh FR, Kanwar YS: Rap1b GTPase ameliorates glucose-induced mitochondrial dysfunction. J Am Soc Nephrol 2008; 19: 2293-2301.
29. Brezniceanu ML, Lau CJ, Godin N, Chenier I, Duclos A, Ethier J, Filep JG, Ingelfinger JR, Zhang SL, Chan JS: Reactive oxygen species promote caspase-12 expression and tubular apoptosis in diabetic nephropathy. J Am Soc Nephrol 2010; 21: 943-954.
30. Lin M, Yiu WH, Wu HJ, Chan LY, Leung JC, Au WS, Chan KW, Lai KN, Tang SC: Tolllike receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol 2012; 23: 86-102.
31. Kudo H, Yata Y, Takahara T, Kawai K, Nakayama Y, Kanayama M, Oya T, Morita S, Sasahara M, Mann DA, Sugiyama T: Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int 2009; 29: 988-996.
32. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H: Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 2006; 48: 51-57. (Pubitemid 44297524)
33. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW: Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47: 1003-1009. (Pubitemid 44297575)